Confronto
Glepaglutide vs. Gonadorelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
nessun dato
33515-09-2
Peso molecolare
nessun dato
1182.29 g/mol
Emivita
nessun dato
0.1 h
Sequenza
nessun dato
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2Meccanismo d'azione
Glepaglutide
As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.
Gonadorelin
Gonadorelin acts as an agonist at the GnRH receptor on the gonadotroph cells of the pituitary and triggers release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The temporal pattern of receptor exposure is decisive: pulsatile administration mimics the natural hypothalamic secretory rhythm and sustains LH/FSH release, whereas continuous exposure leads to receptor internalisation and desensitisation with subsequent paradoxical suppression of gonadotropins. The latter principle is exploited therapeutically by longer-acting GnRH agonists.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
1
4
di cui sull'uomo
1
4
Effetti registrati
2
4
Contraddizioni aperte
0
1
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Glepaglutide and Gonadorelin?
- Glepaglutide is classified as "Ricerca (altro)", while Gonadorelin is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Gonadorelin: Gonadorelin is the synthetic decapeptide with an amino-acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH/LHRH). Historically approved in several countries for diagnostic testing of pituitary function and for fertility indications (pump systems). A defining feature is the opposite effect of pulsatile versus continuous administration: pulsatile stimulates, continuous leads to receptor desensitisation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Glepaglutide or Gonadorelin?
- The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "Studio sull'uomo" for Gonadorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Glepaglutide and Gonadorelin in Germany and the United States?
- Germania: Glepaglutide — Non approvato, Gonadorelin — Su prescrizione. Stati Uniti: Glepaglutide — Non approvato, Gonadorelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.